NAMSA Acquires Labcorp's Early Development Medical Device Testing Business
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Jan 08 2026
0mins
Should l Buy LH?
Source: PRnewswire
- Strategic Acquisition: NAMSA has completed the acquisition of Labcorp's Early Development medical device testing business, further solidifying its leadership position in the global medical device testing sector and expected to accelerate time-to-market for MedTech manufacturers.
- Service Portfolio Expansion: This acquisition allows NAMSA to gain Labcorp's services in biocompatibility testing, microbiological testing, analytical testing, and preclinical research, enhancing its comprehensive solution capabilities across the product lifecycle.
- Customer Service Commitment: NAMSA CEO Brian Smith stated that they will provide Labcorp's medical device clients with a seamless transition, ensuring they receive the same high level of expertise and service that current NAMSA clients expect, thereby enhancing customer satisfaction.
- Increased Industry Influence: This acquisition marks NAMSA's tenth since becoming an ARCHIMED company, demonstrating its ongoing expansion in the medical device development field and commitment to innovation, which is expected to attract more collaboration from MedTech companies.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy LH?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on LH
Wall Street analysts forecast LH stock price to rise
12 Analyst Rating
10 Buy
2 Hold
0 Sell
Strong Buy
Current: 272.740
Low
270.00
Averages
304.45
High
325.00
Current: 272.740
Low
270.00
Averages
304.45
High
325.00
About LH
Labcorp Holdings Inc. provides comprehensive laboratory services that help doctors, hospitals, pharmaceutical companies, researchers and patients. The Company operates through two segments: Diagnostics Laboratories (Dx) and Biopharma Laboratory Services (BLS). The Diagnostics Laboratories segment includes routine testing and specialty/esoteric testing. Dx operates through a network of patient service centers, branches, rapid response laboratories, primary laboratories, and specialty laboratories. The BLS segment provides drug development and CDx development solutions from early-stage research to clinical development, along with support for crop protection and chemical testing, through its ED and Central Laboratory Services businesses. Its service also includes ambulatory outpatient laboratory services. The Company is focused on four primary specialty testing areas, such as oncology, women's health, autoimmune disease, and neurology.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Labcorp to Release Q1 2026 Financial Results on April 30
- Earnings Release Schedule: Labcorp is set to announce its Q1 2026 financial results before the market opens on April 30, 2026, reflecting the company's ongoing leadership in innovative laboratory services.
- Webcast Discussion: The company will host a webcast at 9:00 a.m. ET on the same day to discuss the financial results, enhancing transparency and investor confidence in the company's performance.
- Investor Relations Information: The earnings press release and accompanying financial information will be posted in the 'News & Events' section of Labcorp's investor relations website, facilitating easy access for investors to the latest updates.
- Replay Availability: A replay of the webcast will be available approximately two hours after the live event on the investor relations website for one year, ensuring investors can access important information at their convenience.
See More
Illumina and Labcorp Expand Precision Oncology Collaboration
- Collaboration Deepening: Illumina and Labcorp announced an expanded collaboration to advance precision oncology using next-generation sequencing (NGS) solutions, expected to promote equitable access to cancer biomarker testing and enhance patient convenience.
- New Test Development: The companies will jointly develop tests addressing unmet needs, covering advanced oncology research and in vitro diagnostic (IVD) tests, aiming to bridge gaps in precision oncology and drive advancements in personalized cancer care.
- Liquid and Tissue Biopsy Integration: The collaboration will explore co-commercializing Labcorp's FDA-authorized liquid biopsy PGDx elio® plasma focus™ Dx alongside Illumina's FDA-approved TruSight™ Oncology Comprehensive, aiming to provide broader biomarker testing for hospitals and community health systems.
- Clinical Utility Research: In a joint study, Illumina's CGP detected variants in over 72% of more than 7,600 non-small cell lung cancer samples that had current targeted therapies or clinical trials, demonstrating CGP's effectiveness in identifying tumor genomic features.
See More
Illumina and Labcorp Expand Precision Oncology Collaboration
- Collaboration Deepening: Illumina and Labcorp announced an expanded collaboration aimed at enhancing precision oncology through next-generation sequencing solutions, with expectations to promote equitable access to cancer biomarker testing, thereby improving patient testing convenience.
- New Test Development: The companies will jointly develop tests addressing unmet needs, covering advanced oncology research and in vitro diagnostic tests, aiming to bridge existing gaps in precision oncology and improve patient treatment outcomes.
- Co-Commercialization: Plans include co-commercializing Labcorp's FDA-authorized liquid biopsy assay PGDx elio® plasma focus™ Dx alongside Illumina's FDA-approved TruSight™ Oncology Comprehensive, intended to provide broader access to both tissue and liquid biopsy testing for hospitals and community health systems.
- Clinical Utility Research: The companies will continue joint efforts to demonstrate the clinical utility of CGP, with studies showing that CGP detected variants in over 72% of non-small cell lung cancer patient tumors that are relevant to current targeted therapies or clinical trials, further advancing the application of precision medicine.
See More
Middleby Appoints Glenn Eisenberg to Board of Directors
- Board Expansion: The Middleby Corporation announced the appointment of Glenn Eisenberg to its Board of Directors, effective March 1, increasing the board to twelve members, which underscores the company's commitment to strategic transformation.
- Extensive Financial Experience: Eisenberg brings a 20-year track record as a public company CFO and senior operating executive, having previously served as CFO at Labcorp, overseeing financial operations in over 100 countries, which is expected to significantly support Middleby's operational initiatives.
- Strategic Focus: Middleby CEO Tim FitzGerald noted that Eisenberg's expertise in financial discipline and capital allocation will be crucial for driving sustainable organic growth, reflecting the company's emphasis on enhancing board capabilities.
- Diverse Leadership Background: Eisenberg currently serves on the boards of two other public companies and has extensive public company governance experience, which will provide valuable oversight for Middleby as it aims to achieve long-term value creation and operational excellence.
See More
LABCORP CEO ADAM SCHECHTER DISCLOSES SALE OF 8,705 COMMON SHARES ON MARCH 3 AT $279.9595 EACH, ACCORDING TO SEC FILING
Company Announcement: Labor Corp CEO Adam Schechter reports the open market sale of 8,705 common shares.
Sale Details: The shares were sold on March 3 at a price of $279.95 per share, as disclosed in a SEC filing.
See More
Five Key Principles of Innovation
- Importance of Innovation Culture: Lorraine Marchand emphasizes that successful organizations foster a culture that reframes failure as a learning opportunity, encouraging experimentation and allowing employees to freely express new ideas, thereby enhancing the organization's innovative capacity.
- Investment Strategy in Risk: She notes that successful companies often follow a 70/20/10 investment ratio, with 10% allocated to uncertain innovation projects, a strategy validated by Google's success, indicating that appropriate risk investment can significantly drive company growth.
- Customer-First Strategy: Marchand points out that many companies fail to adjust to changing customer demands, leading to market failures; therefore, investors should focus on a company's customer-oriented strategies to avoid failures similar to those of Blockbuster and Kodak.
- Collaboration and Change Management: She highlights that collaboration has become a strategic imperative for corporate success, and organizations need to prioritize team collaboration during change to achieve breakthrough growth, ensuring that departments work together towards common objectives.
See More
Labcorp to Release Q1 2026 Financial Results on April 30
- Earnings Release Schedule: Labcorp is set to announce its Q1 2026 financial results before the market opens on April 30, 2026, reflecting the company's ongoing leadership in innovative laboratory services.
- Webcast Discussion: The company will host a webcast at 9:00 a.m. ET on the same day to discuss the financial results, enhancing transparency and investor confidence in the company's performance.
- Investor Relations Information: The earnings press release and accompanying financial information will be posted in the 'News & Events' section of Labcorp's investor relations website, facilitating easy access for investors to the latest updates.
- Replay Availability: A replay of the webcast will be available approximately two hours after the live event on the investor relations website for one year, ensuring investors can access important information at their convenience.
See More
Illumina and Labcorp Expand Precision Oncology Collaboration
- Collaboration Deepening: Illumina and Labcorp announced an expanded collaboration to advance precision oncology using next-generation sequencing (NGS) solutions, expected to promote equitable access to cancer biomarker testing and enhance patient convenience.
- New Test Development: The companies will jointly develop tests addressing unmet needs, covering advanced oncology research and in vitro diagnostic (IVD) tests, aiming to bridge gaps in precision oncology and drive advancements in personalized cancer care.
- Liquid and Tissue Biopsy Integration: The collaboration will explore co-commercializing Labcorp's FDA-authorized liquid biopsy PGDx elio® plasma focus™ Dx alongside Illumina's FDA-approved TruSight™ Oncology Comprehensive, aiming to provide broader biomarker testing for hospitals and community health systems.
- Clinical Utility Research: In a joint study, Illumina's CGP detected variants in over 72% of more than 7,600 non-small cell lung cancer samples that had current targeted therapies or clinical trials, demonstrating CGP's effectiveness in identifying tumor genomic features.
See More
Illumina and Labcorp Expand Precision Oncology Collaboration
- Collaboration Deepening: Illumina and Labcorp announced an expanded collaboration aimed at enhancing precision oncology through next-generation sequencing solutions, with expectations to promote equitable access to cancer biomarker testing, thereby improving patient testing convenience.
- New Test Development: The companies will jointly develop tests addressing unmet needs, covering advanced oncology research and in vitro diagnostic tests, aiming to bridge existing gaps in precision oncology and improve patient treatment outcomes.
- Co-Commercialization: Plans include co-commercializing Labcorp's FDA-authorized liquid biopsy assay PGDx elio® plasma focus™ Dx alongside Illumina's FDA-approved TruSight™ Oncology Comprehensive, intended to provide broader access to both tissue and liquid biopsy testing for hospitals and community health systems.
- Clinical Utility Research: The companies will continue joint efforts to demonstrate the clinical utility of CGP, with studies showing that CGP detected variants in over 72% of non-small cell lung cancer patient tumors that are relevant to current targeted therapies or clinical trials, further advancing the application of precision medicine.
See More
Middleby Appoints Glenn Eisenberg to Board of Directors
- Board Expansion: The Middleby Corporation announced the appointment of Glenn Eisenberg to its Board of Directors, effective March 1, increasing the board to twelve members, which underscores the company's commitment to strategic transformation.
- Extensive Financial Experience: Eisenberg brings a 20-year track record as a public company CFO and senior operating executive, having previously served as CFO at Labcorp, overseeing financial operations in over 100 countries, which is expected to significantly support Middleby's operational initiatives.
- Strategic Focus: Middleby CEO Tim FitzGerald noted that Eisenberg's expertise in financial discipline and capital allocation will be crucial for driving sustainable organic growth, reflecting the company's emphasis on enhancing board capabilities.
- Diverse Leadership Background: Eisenberg currently serves on the boards of two other public companies and has extensive public company governance experience, which will provide valuable oversight for Middleby as it aims to achieve long-term value creation and operational excellence.
See More
LABCORP CEO ADAM SCHECHTER DISCLOSES SALE OF 8,705 COMMON SHARES ON MARCH 3 AT $279.9595 EACH, ACCORDING TO SEC FILING
Company Announcement: Labor Corp CEO Adam Schechter reports the open market sale of 8,705 common shares.
Sale Details: The shares were sold on March 3 at a price of $279.95 per share, as disclosed in a SEC filing.
See More
Five Key Principles of Innovation
- Importance of Innovation Culture: Lorraine Marchand emphasizes that successful organizations foster a culture that reframes failure as a learning opportunity, encouraging experimentation and allowing employees to freely express new ideas, thereby enhancing the organization's innovative capacity.
- Investment Strategy in Risk: She notes that successful companies often follow a 70/20/10 investment ratio, with 10% allocated to uncertain innovation projects, a strategy validated by Google's success, indicating that appropriate risk investment can significantly drive company growth.
- Customer-First Strategy: Marchand points out that many companies fail to adjust to changing customer demands, leading to market failures; therefore, investors should focus on a company's customer-oriented strategies to avoid failures similar to those of Blockbuster and Kodak.
- Collaboration and Change Management: She highlights that collaboration has become a strategic imperative for corporate success, and organizations need to prioritize team collaboration during change to achieve breakthrough growth, ensuring that departments work together towards common objectives.
See More
